Journal Mobile Options
Table of Contents
Vol. 39, No. 3, 1999
Issue release date: April 1999

Apolipoprotein E Genotype and Schizophrenia

Chen J.-Y. · Hong C.-J. · Chiu H.-J. · Lin C.-Y. · Bai Y.-M. · Song H.-L. · Lai H.-C. · Tsai S.-J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Schizophrenic disorders are complex genetic disorders and may involve multiple genes of small effect. The presence of apolipoprotein E (apoE) is associated with several neuropsychiatric disorders. Previous studies on apoE genotype distribution in schizophrenia have reported conflicting findings. We studied the genotype frequencies in a large group of schizophrenic patients. The genotype distribution was significantly different between the schizophrenic patients and the control subjects. Persons who were σ3 carriers have an increased risk of schizophrenia. This result suggests that apoE isoforms may play a functional role in the pathogenesis of schizophrenic disorders. Some possible mechanisms regarding the effect of apoE on the development of schizophrenia are discussed.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Poirier J: Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci 1994;17:525–530.
  2. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  3. Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM: Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 1995;202:101–104.

    External Resources

  4. Howard R, Dennehey J, Lovestone S, Birkett J, Sham P, Powell J, Castle D, Murray R, Levy R: Apolipoprotein E genotype and late paraphrenia. Int J Geriatr Psychiatry 1995;10:147–150.
  5. Joober R, Rouleau G, Fon E, Lal S, Palmour R, Bloom D, Labelle A, Benkelfat C: Apolipoprotein E genotype in schizophrenia. Am J Med Genet 1996;67:235.
  6. Zhu S, Nothen MM, Uhlhaas S, Rietschel M, Korner J, Lanczik M, Fimmers R, Propping P: Apolipoprotein E genotype distribution in schizophrenia. Psychiatr Genet 1996;6:75–79.
  7. Arnold SE, Joo E, Martinoli MG, Roy N, Trojanowski JQ, Gur RE, Cannon T, Price RA: Apolipoprotein E genotype in schizophrenia: Frequency, age of onset, and neuropathologic features. Neuroreport 1997;8:1523–1526.

    External Resources

  8. Powchik P, Friedman J, Haroutunian V, Greenberg D, Altsteil L, Purohit D, Perl D, Davidson M: Apolipoprotein E4 in schizophrenia: A study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry 1997;42:296–298.
  9. Town T, Fallin D, Crawford F, Walsh S, Solomon R, Mullan M: Lack of association between the apolipoprotein E epsilon4 allele (APOE epsilon4) and chronic schizophrenia. Am J Med Genet 1997;74:451–452.
  10. Thibaut F, Coron B, Hannequin D, Segard L, Martin C, Dollfus S, Campion D, Frebourg T, Petit M: No association of apolipoprotein epsilon 4 allele with schizophrenia even in cognitively impaired patients. Schizophr Res 1998;30:149–153.
  11. Jonsson E, Lannfelt L, Engvall B, Sedvall G: Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele. Eur Arch Psychiatry Clin Neurosci 1996;246:182–184.
  12. Igata-Yi R, Igata T, Ishizuka K, Kimura T, Sakamoto S, Katsuragi S, Takamatsu J, Miyakawa T: Apolipoprotein E genotype and psychosis. Biol Psychiatry 1997;41:906–908.
  13. Lan TH, Hong CJ, Chen JY, Sim CB: Apolipoprotein E-epsilon 4 frequency in patients with schizophrenia. Biol Psychiatry 1997;42:225–227.
  14. Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
  15. Pickar D, Malhotra AK, Rooney W, Breier A, Goldman D: Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 1997;350:930–931.
  16. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW: Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987;917:148–161.
  17. Mahadik SP, Mukherjee S: Free radical pathology and antioxidant defense in schizophrenia: A review. Schizophr Res 1996;19:1–17.
  18. Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55–61.
  19. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE: Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science 1994;264:850–852.
  20. Ohara K, Nagai M, Ohara K: Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 1997;350:1857.

    External Resources

  21. Arnold SE, Trojanowski JQ: Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology. Schizophr Bull 1996;22:5–9.
  22. Boston PF, Dursun SM, Reveley MA: Cholesterol and mental disorder. Br J Psychiatry 1996;169:682–689.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00